04.06.2024 - CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock .
The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22
Vor Biopharma s (VOR) Outperform Rating Reaffirmed at Oppenheimer theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Here are five things to know about 2024 Commencement speaker Siddhartha Mukherjee thedp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedp.com Daily Mail and Mail on Sunday newspapers.
VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024 biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.